US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPUS GENETICS INC

0.8402

+0.04025.03%

Post-market: 0.84920.0090+1.07%18:44 EDT

Volume:162.62K

Turnover:130.10K

Market Cap:38.22M

PE:-0.39

High:0.8402

Open:0.7956

Low:0.7542

Close:0.8000

Loading ...

Overview Company News Filings

Press Release: Opus Genetics Announces Financial Results for Full Year 2024

Several Insiders Invested In Opus Genetics Flagging Positive News

Simply Wall St.

BRIEF-Opus Genetics founder Mina Sooch files preliminary proxy materials for co board election

Opus Genetics Inc - Believes That Current Board's Strategic, Management and Capital Allocation Failures Have Resulted in Stockholder Value Destruction

THOMSON REUTERS

Opus Genetics Inc - Mina Sooch Files Preliminary Proxy Materials for Opus Genetics Board Election

THOMSON REUTERS

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Prices Public Offering, Private Placement

MT Newswires Live

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement With Proceeds of Over $20 Million

THOMSON REUTERS

Opus Genetics Inc - Proceeds to Fund Clinical Development of Lead Gene Therapy Programs

THOMSON REUTERS

Press Release: Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Opus Genetics Inc: Complaint Seeks, Among Other Relief, Equitable Relief Enjoining Sandoz From Infringing Ryzumvi™ Patents

THOMSON REUTERS

Opus Genetics Inc: Intends to Vigorously Enforce Its Intellectual Property Rights Relating to Ryzumvi™

THOMSON REUTERS

Opus Genetics Inc: on March 14, Filed Complaint for Patent Infringement of Certain Ryzumvi™ Patents Against Sandoz Inc. in District of New Jersey

THOMSON REUTERS

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Iron Road (ASX:IRD) Is Looking To Continue Growing Its Returns On Capital

Simply Wall St.

Opus Genetics announces presentations at ARVO 2025 meeting

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

BRIEF-Opus Genetics In Jan, Got Paragraph IV Certification Notice From Winston & Strawn, Counsel To Sandoz Incorporated

Opus Genetics- Sandoz Submitted Anda to FDA Seeking Approval to Manufacture Generic Version of Ryzumvitm in US Prior Expiration of Six Patents

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IRD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":0.8402,"timestamp":1745611200000,"preClose":0.8,"halted":0,"volume":162623,"hourTrading":{"tag":"盘后","latestPrice":0.8492,"preClose":0.8402,"latestTime":"18:44 EDT","volume":797,"amount":681.8108,"timestamp":1745621084226},"delay":0,"floatShares":36127791,"shares":45483823,"eps":-2.153504,"marketStatus":"Market Closed","change":0.0402,"latestTime":"04-25 16:00:00 EDT","open":0.7956,"high":0.8402,"low":0.7542,"amount":130101.92891909998,"amplitude":0.1075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.153504,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":0.8,"preHourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.8,"latestTime":"08:57 EDT","volume":123,"amount":98.4599994,"timestamp":1745585844295},"postHourTrading":{"tag":"盘后","latestPrice":0.8492,"preClose":0.8402,"latestTime":"18:44 EDT","volume":797,"amount":681.8108,"timestamp":1745621084226},"volumeRatio":1.143454403133233,"impliedVol":2.1502,"impliedVolPercentile":0.544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":36127791,"roa":"-46.90%","roe":"-152.46%","lyrEps":-2.153504,"volumeRatio":1.143454403133233,"shares":45483823,"dividePrice":0,"high":0.8402,"amplitude":0.1075,"preClose":0.8,"low":0.7542,"week52Low":0.65,"pbRate":"5.68","psRate":"3.48","week52High":2.18,"institutionHeld":0,"latestPrice":0.8402,"eps":-2.153504,"divideRate":0,"volume":162623,"delay":0,"ttmEps":-2.153504,"open":0.7956,"prevYearClose":1.19,"prevWeekClose":0.7599,"prevMonthClose":0.9818,"prevQuarterClose":0.9818,"fiveDayClose":0.7599,"twentyDayClose":0.9903,"sixtyDayClose":1.08},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523469849","title":"Press Release: Opus Genetics Announces Financial Results for Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2523469849","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523469849?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:20","pubTimestamp":1743423600,"startTime":"0","endTime":"0","summary":"Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases. Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance. New capital supports delivery on key milestones for two lead gene therapy candidates OPGx-LCA5 and OPGx-BEST1. \"Looking ahead, we see several near-term catalysts on the horizon. We expect to announce up to four clinical trial data readouts in 2025, including Phase 3 data on dim light vision disturbances and in presbyopia for Phentolamine Ophthalmic Solution 0.75%. We also expect our second gene therapy candidate, OPGx-BEST1, to enter the clinic later this year. With a strengthened pipeline of promising gene therapies, a strong cash position, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2522807508","title":"Several Insiders Invested In Opus Genetics Flagging Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=2522807508","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522807508?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:04","pubTimestamp":1742994246,"startTime":"0","endTime":"0","summary":"It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Opus Genetics, Inc.'s  case, it's fantastic news for shareholders.While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.Opus Genetics Insider Transactions Over The Last Year. In the last twelve months, the biggest single purchase by an insider was when CEO & Director George Magrath bought US$101k worth of shares at a price of US$1.02 per share. That means that an insider was happy to buy shares at around the current price of US$1.13. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Opus Genetics share holders is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/several-insiders-invested-opus-genetics-130406211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2521257601","title":"BRIEF-Opus Genetics founder Mina Sooch files preliminary proxy materials for co board election","url":"https://stock-news.laohu8.com/highlight/detail?id=2521257601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521257601?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:09","pubTimestamp":1742591398,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics founder Mina Sooch files preliminary proxy materials for co board electionMarch 21 (Reuters) - Opus Genetics Inc IRD.O:OPUS GENETICS INC - MINA SOOCH FILES PRELIMINARY PROXY MATERI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q41CE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2521257585","title":"Opus Genetics Inc - Believes That Current Board's Strategic, Management and Capital Allocation Failures Have Resulted in Stockholder Value Destruction","url":"https://stock-news.laohu8.com/highlight/detail?id=2521257585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521257585?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:05","pubTimestamp":1742591115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q41CE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2521225758","title":"Opus Genetics Inc - Mina Sooch Files Preliminary Proxy Materials for Opus Genetics Board Election","url":"https://stock-news.laohu8.com/highlight/detail?id=2521225758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521225758?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:05","pubTimestamp":1742591115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nFWN3Q41CE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2521257737","title":"Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2521257737","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521257737?lang=en_us&edition=fundamental","pubTime":"2025-03-22 05:03","pubTimestamp":1742590980,"startTime":"0","endTime":"0","summary":"Believes that Current Board’s Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction. Highlights Serious Concerns with the Opus Merger and the Company’s Underperformance. Preliminary Proxy Materials Present an Alternative Strategy to Create Significant Stockholder Value Without Extreme Dilution. Mina Sooch stated: “It is time for the stockholders to have a real voice at the Annual Meeting and new leadership on the Board. The Board has made a series of ill-advised corporate actions to entrench their position at the expense of stockholders. Stockholders should be outraged by the massive stockholder dilution, all while providing limited communication. Rather than maximizing the value of RYZUMVI—an FDA-approved, de-risked asset with zero capital requirements, extensive patient data, and significant upside—the Board has chosen to shift focus to capital-intensive, early-stage gene therapy assets with data presented in only three patients. Further","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/restore-value-slate-led-mina-210300068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARKG","BK4007","XBI","IRD","BK4585","BK4581","BK4544","BK4588"],"gpt_icon":0},{"id":"2521844262","title":"Opus Genetics Prices Public Offering, Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2521844262","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521844262?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:32","pubTimestamp":1742563950,"startTime":"0","endTime":"0","summary":"Opus Genetics  said Friday that it has priced a $20 million underwritten public offering, as well as a concurrent private placement for gross proceeds of $1.5 million.The ophthalmic biotechnology company said there will also be up to $21.4 million in additional proceeds when the warrants are exercised. The offerings are expected to close Monday.Opus said the net proceeds will be used to fund the clinical development of its lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, as well as general corporate purposes and working capital.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD","BK7129","BK4007","IRD.AU"],"gpt_icon":0},{"id":"2521728159","title":"Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement With Proceeds of Over $20 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521728159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521728159?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:11","pubTimestamp":1742562708,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA8LHVKM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2521518281","title":"Opus Genetics Inc - Proceeds to Fund Clinical Development of Lead Gene Therapy Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521518281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521518281?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:11","pubTimestamp":1742562708,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA8LHVKM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2521281557","title":"Press Release: Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521281557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521281557?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:11","pubTimestamp":1742562660,"startTime":"0","endTime":"0","summary":"Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million. The concurrent private placement is comprised of 1,176,471 shares of common stock and 1,176,471 warrants to purchase shares of common stock, at an offering price of $1.275. The warrants will be exercisable immediately upon issuance, have an initial exercise price of $1.15, expire on the five-year anniversary of the original issuance date and may be called by the Company 30 days following the release of the Company's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of a volume weighted average price of o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCA","IRD","BK4007"],"gpt_icon":0},{"id":"2521037934","title":"North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521037934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521037934?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:02","pubTimestamp":1742551320,"startTime":"0","endTime":"0","summary":"The euphoria from the Federal Reserve's policy meeting didn't last long.Stock futures were lower Friday as attention shifted from the Fed to the prospect of further tariffs.Trump said in a social media post that the planned imposition of reciprocal tariffs on April 2 would be \"Liberation Day\" in the U.S.\"We maintain our view that the FOMC outcome was effectively a one-day move, with minimal legacy in terms of immediate direction. That said, we also view the FOMC outcome as a whole as nodding towards dovishness, but with numerous caveats,\" ING said.Quantum-computing stocks  are likely to be in focus after suffering steep falls on Thursday as investors appeared unimpressed by their contributions to Nvidia's Quantum Day at its GTC developers' event.The market also faces a test as an estimated $4.5 trillion in options contracts expire, which could increase volatility.FedEx fell 5.1% off hours after it cut its outlook for the year.Lennar management warned investors of a weak housing market.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDA","DXYN","FBRX","US10Y.BOND","NVDS","NVDX","USAU","3NVD.UK","CKPT","ATXI","FBLG","US30Y.BOND","US7Y.BOND","BOLD","XOMA","ET","IMRX","US3Y.BOND","DM","NVDD","NVD2.UK","MPU","NGNE","NVD3.UK","JVA","PURE","SGMA","NVDU","US5Y.BOND","NVIW.SI","NVDS.UK","2NVD.UK","NVDY","SNVD.UK","NVDL","ZBIO","CCL","BPTH","ADVM","AFG","GORV","IMNM","US6M.BOND","OLMA","US2Y.BOND","PRPH","US12M.BOND","IRD","SMXT"],"gpt_icon":1},{"id":"2520454284","title":"Opus Genetics Inc: Complaint Seeks, Among Other Relief, Equitable Relief Enjoining Sandoz From Infringing Ryzumvi™ Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2520454284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520454284?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:30","pubTimestamp":1742477411,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30YO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2520454280","title":"Opus Genetics Inc: Intends to Vigorously Enforce Its Intellectual Property Rights Relating to Ryzumvi™","url":"https://stock-news.laohu8.com/highlight/detail?id=2520454280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520454280?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:30","pubTimestamp":1742477411,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30YO:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2520236454","title":"Opus Genetics Inc: on March 14, Filed Complaint for Patent Infringement of Certain Ryzumvi™ Patents Against Sandoz Inc. in District of New Jersey","url":"https://stock-news.laohu8.com/highlight/detail?id=2520236454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520236454?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:30","pubTimestamp":1742477411,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2520319836","title":"Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520319836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520319836?lang=en_us&edition=fundamental","pubTime":"2025-03-20 03:56","pubTimestamp":1742414178,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUABMMXYH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2517908085","title":"Iron Road (ASX:IRD) Is Looking To Continue Growing Its Returns On Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908085","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517908085?lang=en_us&edition=fundamental","pubTime":"2025-03-06 04:52","pubTimestamp":1741207974,"startTime":"0","endTime":"0","summary":"If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ird/iron-road-shares/news/iron-road-asxird-is-looking-to-continue-growing-its-returns","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7129","IRD.AU","IRD","BK4007","EBIT"],"gpt_icon":0},{"id":"2517911785","title":"Opus Genetics announces presentations at ARVO 2025 meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911785?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:17","pubTimestamp":1741180641,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) announced that three abstracts on its investigational gene therapy candidates have been accepted for presentation at the Associ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-announces-presentations-at-arvo-2025-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-announces-presentations-at-arvo-2025-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2517775919","title":"Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517775919","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517775919?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:00","pubTimestamp":1741179600,"startTime":"0","endTime":"0","summary":"New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One Year. Durham, NC., March 05, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases  and other ophthalmologic disorders, today announced that three abstracts on its investigational gene therapy candidates have been accepted for presentation at the Association for Research in Vision and Ophthalmology 2025 Meeting, to take place May 4-8, 2025 in Salt Lake City, UT. The abstracts feature 12-month data from the first three adult patients in our ongoing Phase 1/2 trial of OPGx-LCA5, as well as pre-clinical results on OPGx-MERTK and OPGx-RDH12.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-presentations-association-130000355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IRD","LCA"],"gpt_icon":0},{"id":"2517717984","title":"BRIEF-Opus Genetics In Jan, Got Paragraph IV Certification Notice From Winston & Strawn, Counsel To Sandoz Incorporated","url":"https://stock-news.laohu8.com/highlight/detail?id=2517717984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517717984?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:03","pubTimestamp":1741125828,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics In Jan, Got Paragraph IV Certification Notice From Winston & Strawn, Counsel To Sandoz IncorporatedMarch 4  - Opus Genetics Inc IRD.O:OPUS GENETICS- IN JAN, GOT PARAGRAPH IV CERTIFICATION NOTICE FROM WINSTON & STRAWN, COUNSEL TO SANDOZ INCORPORATEDOPUS GENETICS- SANDOZ SUBMITTED ANDA TO FDA SEEKING APPROVAL TO MANUFACTURE GENERIC VERSION OF RYZUMVITM IN US PRIOR EXPIRATION OF SIX PATENTSFurther company coverage: IRD.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN10K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2517984989","title":"Opus Genetics- Sandoz Submitted Anda to FDA Seeking Approval to Manufacture Generic Version of Ryzumvitm in US Prior Expiration of Six Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2517984989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517984989?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:55","pubTimestamp":1741125344,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN10K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":74,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-08-13","symbol":"IRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":-0.3},{"market":"US","date":"2024-05-10","symbol":"IRD","fiscalQuarterEnding":"2024/03","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"pre","actualEps":-0.29},{"market":"US","date":"2024-03-08","symbol":"IRD","fiscalQuarterEnding":"2023/12","expectedEps":-0.07,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1709874000000,"reportTimeType":"pre","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1744430400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2025-04-25","current":-0.632466,"percent":0.92562,"low":-2.964142,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"high":-0.560128,"avg":-1.33286,"sd":0.500679,"marketCap":36387058},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058}],"updateTime":1745702153664}}}